Bioorthogonal Cascade-Targeting: Directing Drugs into Cells with Molecular Precision

Develop bioorthogonal cascade-targeting methods for precise, safe, and efficient intracellular delivery of therapeutics, enhancing drug targeting and minimizing collateral damage.

Subsidie
€ 1.479.321
2023

Projectdetails

Introduction

Bioorthogonal chemistries cross the boundaries between static chemical connectivity and the dynamic physiologic regulation of molecular state, enabling powerful tools for molecular control in complex biological environments. In combination with ligand-directed drug delivery, safe and selective chemical reactions that perform efficiently in vivo can fuel the design of new therapeutic strategies.

Challenges in Drug Targeting

Despite significant progress in the field of drug targeting, it remains challenging to shuttle therapeutic agents to the desired tissue, reaching the necessary cellular and even sub-cellular level, all while avoiding collateral damage.

Proposed Solution

To engage this challenge, I aim to develop the concept of bioorthogonal cascade-targeting to direct the recognition, activation, and intracellular delivery of therapeutic constructs with molecular precision.

Development of Chemical Tools

We will develop next-level chemical tools for bioorthogonal bond-cleavage with exceptional reaction performance and the unique capability of tunable sequential release events (‘tandem release’). These innovations will enable us to design bioorthogonally activatable ligands for multiple therapeutic approaches that open new ground, most notably in escalating the complexity of (bio)chemical choreography.

Cascade Processes

In particular, I propose cascade processes, triggered by a single biocompatible click event, that can achieve:

  1. The ‘bridging’ of non-internalizing cell-surface receptors to forward therapeutics into cells.
  2. The ‘hopping’ of drug conjugates from one target to another, or from one cell to another.
  3. Kinetically preprogrammed ‘escape’ of drugs from the endosomal compartment of cells entered via cascade-targeting.

Conclusion

This will allow us to spatially and temporally control the movement and release of therapeutics in a (sub)cellular environment, and ultimately to establish bioorthogonal cascades as unique strategies that shift the paradigm of biologically controlled drug delivery.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.479.321
Totale projectbegroting€ 1.479.321

Tijdlijn

Startdatum1-1-2023
Einddatum31-12-2027
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • TECHNISCHE UNIVERSITAET WIENpenvoerder

Land(en)

Austria

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Bioorthogonal Iontronic Chemistry: Spatiotemporal Drug Release with Electronic Precision

Develop a programmable drug delivery system using Biontronic Chemistry for precise spatiotemporal release, enhancing treatment efficacy while minimizing side effects in various therapies.

€ 1.496.795
ERC Consolid...

A general approach for the design of covalent protein proximity inducers

This project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications.

€ 1.998.744
ERC Proof of...

Mix and Match: One-step activation for targeted drug delivery

This project aims to develop a novel, efficient method for on-demand attachment of targeting ligands to nanocarriers, enhancing drug delivery efficacy while reducing toxicity in cancer therapies.

€ 150.000
ERC Starting...

Creating an orthogonal gate to the brain

This project aims to revolutionize brain drug delivery by creating a novel orthogonal receptor for efficient transport across the blood-brain barrier, targeting treatments for brain metastatic breast cancer.

€ 1.499.136
ERC Advanced...

Functional Nanoscale Therapeutics

Develop functional hybrid nanoscale medicines to enhance intracellular delivery of mRNA and combat nanoscale pathogens, aiming for advanced therapies against diseases like cancer.

€ 2.499.796

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics

The project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer.

€ 4.420.511
EIC Pathfinder

On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic Drugs

Develop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery.

€ 2.606.250
EIC Pathfinder

SUPRAMOLECULAR AGENTS AS RADIOTHERANOSTIC DRUGS

SMARTdrugs aims to revolutionize cancer treatment by developing supramolecular radiotheranostics that integrate diagnostics and therapy for targeted drug delivery.

€ 2.135.087